The latest update is out from Aspira Women’s Health ( (AWHL)). On December 29, 2025, Aspira Women’s Health published a new investor presentation outlining how its AI-powered, multi-omic diagnostic ...

The proposed rule would allow for OvaWatchSM to be reimbursed at the same rate as Ova1® at $897 per test and will become final following a brief public comment period AUSTIN, Texas, Nov. 09, ...

Early detection of ovarian cancer, the deadliest gynecologic cancer, is crucial for reducing mortality. Current noninvasive risk assessment measures include protein biomarkers in combination with ...

AIM is a wholly owned subsidiary of Anthem, Inc., serving more than 50 million members across 50 states, D.C., and US territories. AUSTIN, Texas, July 08, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s ...

AUSTIN, Texas, July 08, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH) today announced its OVA1 ® risk assessment test for ovarian cancer in women with pelvic masses is considered ...

Second Largest Medicaid population in the U.S. AUSTIN, Texas, March 15, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH), today announced its wholly owned subsidiary, Aspira Labs, is ...

- Milestone data announced during Ovarian Cancer Awareness Month, which demonstrates OVA1’s superior sensitivity of ovarian cancer risk detection in both Caucasian and African American women versus ...

Data showing detection improvements across all populations, with marked improvement in detecting ovarian malignancy risk in the African American population Findings to be published in Biomarkers in ...

"We are pleased to expand the in-network coverage for OVA1 with the signing of these agreements," said Fred Ferrara, Chief Operating Officer of Vermillion, Inc. "These agreements increase coverage in ...